Hugoton plant: biotechnology renewed Abengoa's Hugoton plant. Producing cellulosic ethanol for much more than biofuel. Innovative technology solutions for sustainability. By: Abengoa … Continue reading →

Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services.[1] From its inception, biotechnology has maintained a close relationship with society. Although now most often associated with the development of drugs, historically biotechnology has been principally associated with food, addressing such issues as malnutrition and famine. The history of biotechnology begins with zymotechnology, which commenced with a focus on brewing techniques for beer. By World War I, however, zymotechnology would expand to tackle larger industrial issues, and the potential of industrial fermentation gave rise to biotechnology. However, both the single-cell protein and gasohol projects failed to progress due to varying issues including public resistance, a changing economic scene, and shifts in political power. Yet the formation of a new field, genetic engineering, would soon bring biotechnology to the forefront of science in society, and the intimate relationship between the scientific community, the public, and the government would ensue. These debates gained exposure in 1975 at the Asilomar Conference, where Joshua Lederberg was the most outspoken supporter for this emerging field in biotechnology. By as early as 1978, with the synthesis of synthetic human insulin, Lederberg's claims would prove … Continue reading →

Graphics Gallery is a series of labeled diagrams with explanations representing the important processes of biotechnology. Each diagram is followed by a summary of information, providing a context for the process illustrated. The major actors of molecular biology: the nucleic acids, DNA and RNA. How they carry and transfer genetic information from one cell generation to the next and translate this coded information into active proteins. From atoms to molecules and cells to tissues, a study of structure and function. Eucaryotic cell duplication: how chromosomes and genes transmit the information from one mother cell to subsequent generations. From the existing techniques of DNA cloning to gene therapy: understanding the present and a look at the future of genetic engineering. From Mendel to hemophilia: introduction to the major principles of heredity. biological inheritance influences what and who we are. Genetic messengers surrounded by a protein coat. Cells and how they operate See the original post: Graphics Gallery - Access Excellence … Continue reading →

Cytos Biotechnology Ltd announces change in Executive Board Schlieren (Zurich), Switzerland, October 27, 2014 - Cytos Biotechnology Ltd. (SIX:CYTN) ("Cytos" or the "Company") announced today that Mr. Matthias Alder, Executive Vice President Corporate Development and Legal Affairs, resigns from his function effective as of October 27, 2014. The departure of Mr. Alder follows in the course of the winding down of key operational activities of the Company. Mr. Alder has agreed to continue his service to the Company as a consultant until February 28, 2015 to complete ongoing projects and facilitate the transition of his responsibilities. For further information, please contact: Cytos Biotechnology Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 harry.welten@cytos.com About Cytos Biotechnology Ltd Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words … Continue reading →